ALK and cancer: Anaplastic lymphoma kinase (ALK)‐rearrangement (also known as ALK fusion) accounts for 3%–11% in non‐small cell lung cancer (NSCLC) which is the leading cause of cancer‐related death in China and worldwide.1, 2